Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis
Arthritis & Rheumatology · 2025
DOI: 10.1002/art.43069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Denis Poddubnyy und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Toronto, Toronto, Ontario, Canada, and Charité-Universitätsmedizin, Berlin, Germany. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Heterocyclic Compounds, 3-Ring, Axial Spondyloarthritis, Uveitis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Objective
To assess the development of extramusculoskeletal manifestations (EMMs) among patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with upadacitinib 15 mg.
Methods
Data (cutoff: August 15, 2022) from five clinical trials in PsA (2), radiographic axSpA (r‐axSpA; previously ankylosing spondylitis) (2), and nonradiographic axSpA (nr‐axSpA) (1) were analyzed. Treatment‐emergent adverse events of EMMs including uveitis, inflammatory bowel disease (IBD), and psoriasis were assessed in patients treated with placebo, upadacitinib 15 mg, or adalimumab (PsA only) and are reported as exposure‐adjusted event rates (events per 100 patient‐years [E/100 PY]).
Results
Most patients (87.1%–99.3%) did not have a history of EMMs at baseline. In PsA, development of uveitis and IBD were low regardless of treatment or prior EMM history; rates were similar with upadacitinib 15 mg and adalimumab. In r‐axSpA, development of uveitis was numerically lower (E/100 PY) in patients treated with upadacitinib 15 mg (2.8) versus placebo (7.5) and in patients with no history of uveitis (upadacitinib 15 mg 0.6; placebo 1.2) versus a history of uveitis (upadacitinib 15 mg 2.1; placebo 6.2); occurrence of IBD and psoriasis were low regardless of treatment or history. In nr‐axSpA, development of uveitis was low regardless of history but was numerically lower in patients treated with upadacitinib 15 mg (0.9) versus placebo (2.1); occurrence of IBD and psoriasis were low or absent.
Conclusion
In patients with spondyloarthritis, development of EMMs was generally low with upadacitinib 15 mg. Uveitis was numerically lower in patients treated with upadacitinib 15 mg versus placebo, and particularly in r‐axSpA. Regardless of treatment in r‐axSpA, having a history of uveitis appeared to predispose patients for future uveitis events. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Toronto, Toronto, Ontario, Canada, and Charité-Universitätsmedizin, Berlin, Germany.
- AbbVie, Inc, North Chicago, Illinois.
- Ghent University Hospital and Ghent University, Ghent, Belgium.
- Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
- University of Glasgow, Glasgow, United Kingdom.
- Washington University School of Medicine, St. Louis, Missouri.
ORCID-Profile: Denis Poddubnyy, Dirk Elewaut, Stefan Siebert, Michael Paley
Förderung
- AbbVie
Zitieren
APA
Poddubnyy, D., Parikh, B., Elewaut, D., Navarro-Compán, V., Siebert, S., Paley, M., Coombs, D., Lagunes, I., Biljan, A., Nakasato, P., Wung, P., & Lubrano, E. (2025). Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.43069
Vancouver
Poddubnyy D, Parikh B, Elewaut D, Navarro-Compán V, Siebert S, Paley M, et al. Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis. Arthritis & Rheumatology. 2025. doi:10.1002/art.43069
BibTeX
@article{Poddubnyy2025,
author = {Poddubnyy, Denis and Parikh, Bhumik and Elewaut, Dirk and Navarro-Compán, Victoria and Siebert, Stefan and Paley, Michael and Coombs, Derek and Lagunes, Ivan and Biljan, Ana and Nakasato, Priscila and Wung, Peter and Lubrano, Ennio},
title = {Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis},
journal = {Arthritis & Rheumatology},
year = {2025},
doi = {10.1002/art.43069}
}
EUVIMED